EGF activates TTP expression by activation of ELK-1 and EGR-1 transcription factors

BMC Molecular Biology

Volumn 13, Issue , 2012, Pages

  Florkowska, Magdalena ^a   Tymoszuk, Piotr ^a   Balwierz, Aleksandra ^a   Skucha, Anna ^a   Kochan, Jakub ^a   Wawro, Mateusz ^a   Stalinska, Krystyna ^a   Kasza, Aneta ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR ELK 1; TRISTETRAPROLIN; EARLY GROWTH RESPONSE FACTOR 1; ZFP36 PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; BINDING SITE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; SEQUENCE ANALYSIS; CELL LINE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROTEIN BINDING; TRANSCRIPTION INITIATION;

BASE SEQUENCE; CELL LINE; EARLY GROWTH RESPONSE PROTEIN 1; EPIDERMAL GROWTH FACTOR; ETS-DOMAIN PROTEIN ELK-1; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; TRANSCRIPTIONAL ACTIVATION; TRISTETRAPROLIN;

EID: 84858378913     PISSN: None     EISSN: 14712199     Source Type: Journal    
DOI: 10.1186/1471-2199-13-8     Document Type: Article

References (44)

1. Blackshear PJ. Tristetraprolin and other CCCH tandem zinc-finger proteins in the regulation of mRNA turnover. Biochem Soc Trans 2002, 30:945-52.
2. Hudson BP, Martinez-Yamout MA, Dyson HJ, Wright PE. Recognition of the mRNA AU-rich element by the zinc finger domain of TIS11d. Nat Struct Mol Biol 2004, 11:257-64. 10.1038/nsmb738, 14981510.
3. Hau HH, Walsh RJ, Ogilvie RL, Williams DA, Reilly CS, Bohjanen PR. Tristetraprolin recruits functional mRNA decay complexes to ARE sequences. J Cell Biochem 2007, 100:1477-92. 10.1002/jcb.21130, 17133347.
4. Stoecklin G, Tenenbaum SA, Mayo T, Chittur SV, George AD, Baroni TE, Blackshear PJ, Anderson P. Genome-wide analysis identifies interleukin-10 mRNA as target of tristetraprolin. J Biol Chem 2008, 283:11689-99. 10.1074/jbc.M709657200, 2431067, 18256032.
5. Ishmael FT, Fang X, Galdiero MR, Atasoy U, Rigby WF, Gorospe M, Cheadle C, Stellato C. Role of the RNA-binding protein tristetraprolin in glucocorticoid-mediated gene regulation. J Immunol 2008, 180:8342-53. 2505276, 18523301.
6. Al-Souhibani N, Al-Ahmadi W, Hesketh JE, Blackshear PJ, Khabar KS. The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes. Oncogene 2010, 29:4205-15. 10.1038/onc.2010.168, 20498646.
7. Tudor C, Marchese FP, Hitti E, Aubareda A, Rawlinson L, Gaestel M, Blackshear PJ, Clark AR, Saklatvala J, Dean JL. The p38 MAPK pathway inhibits tristetraprolin-directed decay of interleukin-10 and pro-inflammatory mediator mRNAs in murine macrophages. FEBS Lett 2009, 583:1933-8. 10.1016/j.febslet.2009.04.039, 19416727.
8. Deleault KM, Skinner SJ, Brooks SA. Tristetraprolin regulates TNF TNF-alpha mRNA stability via a proteasome dependent mechanism involving the combined action of the ERK and p38 pathways. Mol Immunol 2008, 45:13-24. 10.1016/j.molimm.2007.05.017, 17606294.
9. Brooks SA, Connolly JE, Rigby WF. The role of mRNA turnover in the regulation of tristetraprolin expression: evidence for an extracellular signal-regulated kinase-specific, AU-rich element-dependent, autoregulatory pathway. J Immunol 2004, 172:7263-71.
10. Brook M, Tchen CR, Santalucia T, McIlrath J, Arthur JS, Saklatvala J, Clark AR. Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways. Mol Cell Biol 2006, 26:2408-18. 10.1128/MCB.26.6.2408-2418.2006, 1430283, 16508015.
11. Ronkina N, Kotlyarov A, Dittrich-Breiholz O, Kracht M, Hitti E, Milarski K, Askew R, Marusic S, Lin LL, Gaestel M, Telliez JB. The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol Cell Biol 2007, 27:170-81. 10.1128/MCB.01456-06, 1800641, 17030606.
12. Stoecklin G, Stubbs T, Kedersha N, Wax S, Rigby WF, Blackwell TK, Anderson P. MK2-induced tristetraprolin: 14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J 2004, 23:1313-24. 10.1038/sj.emboj.7600163, 381421, 15014438.
13. Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 1998, 281:1001-5.
14. Hitti E, Iakovleva T, Brook M, Deppenmeier S, Gruber AD, Radzioch D, Clark AR, Blackshear PJ, Kotlyarov A, Gaestel M. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol 2006, 26:2399-407. 10.1128/MCB.26.6.2399-2407.2006, 1430282, 16508014.
15. King EM, Kaur M, Gong W, Rider CF, Holden NS, Newton R. Regulation of tristetraprolin expression by IL-1{beta} and dexamethasone in human pulmonary epithelial cells: Roles for NF-κB and p38 MAPK. J Pharmacol Exp Ther 2009, 330:575-85. 10.1124/jpet.109.151423, 19435930.
16. Suzuki K, Nakajima H, Ikeda K, Maezawa Y, Suto A, Takatori H, Saito Y, Iwamoto I. IL-4-Stat6 signaling induces tristetraprolin expression and inhibits TNF-alpha production in mast cells. J Exp Med 2003, 198:1717-27. 10.1084/jem.20031701, 2194141, 14638848.
17. Ogawa K, Chen F, Kim YJ, Chen Y. Transcriptional regulation of tristetraprolin by transforming growth factor-beta in human T cells. J Biol Chem 2003, 278:30373-81. 10.1074/jbc.M304856200, 12754205.
18. Lai WS, Thompson MJ, Taylor GA, Liu Y, Blackshear PJ. Promoter analysis of Zfp-36, the mitogen-inducible gene encoding the zinc finger protein tristetraprolin. J Biol Chem 1995, 270:25266-72. 10.1074/jbc.270.42.25266, 7559666.
19. Lai WS, Thompson MJ, Blackshear PJ. Characteristics of the intron involvement in the mitogen-induced expression of Zfp-36. J Biol Chem 1998, 273:506-17. 10.1074/jbc.273.1.506, 9417109.
20. Mo Y, Vaessen B, Johnston K, Marmorstein R. Structure of the elk-1-DNA complex reveals how DNA-distal residues affect ETS domain recognition of DNA. Nat Struct Biol 2000, 4:292-7.
21. Ling Y, Lakey JH, Roberts CE, Sharrocks AD. Molecular characterization of the B-box protein-protein interaction motif of the ETS-domain transcription factor Elk-1. EMBO J 1997, 16:2431-40. 10.1093/emboj/16.9.2431, 1169843, 9171356.
22. Yang SH, Vickers E, Brehm A, Kouzarides T, Sharrocks AD. Temporal recruitment of the mSin3A-histone deacetylase corepressor complex to the ETS domain transcription factor Elk-1. Mol Cell Biol 2001, 21:2802-14. 10.1128/MCB.21.8.2802-2814.2001, 86910, 11283259.
23. Yang SH, Sharrocks AD. PIASx acts as an Elk-1 coactivator by facilitating derepression. EMBO J 2005, 24:2161-71. 10.1038/sj.emboj.7600690, 1150884, 15920481.
24. Stefano L, Rössler OG, Griesemer D, Hoth M, Thiel G. P2X(7) receptor stimulation upregulates Egr-1 biosynthesis involving a cytosolic Ca(2+) rise, transactivation of the EGF receptor and phosphorylation of ERK and Elk-1. J Cell Physiol 2007, 213:36-44. 10.1002/jcp.21085, 17474086.
25. O'Donnell A, Yang SH, Sharrocks AD. MAP kinase-mediated c-fos regulation relies on a histone acetylation relay switch. Mol Cell 2008, 29:780-5. 10.1016/j.molcel.2008.01.019, 18374651.
26. Li W, Whaley CD, Bonnevier JL, Mondino A, Martin ME, Aagaard-Tillery KM, Mueller DL. CD28 signaling augments Elk-1-dependent transcription at the c-fos gene during antigen stimulation. J Immunol 2001, 167:827-35.
27. Ling Y, Lakey JH, Roberts CE, Sharrocks AD. Molecular characterization of the B-box protein-protein interaction motif of the ETS-domain transcription factor Elk-1. EMBO J 1997, 16:2431-40. 10.1093/emboj/16.9.2431, 1169843, 9171356.
28. Kasza A, O'Donnell A, Gascoigne K, Zeef LA, Hayes A, Sharrocks AD. The ETS domain transcription factor Elk-1 regulates the expression of its partner protein, SRF. J Biol Chem 2005, 280:1149-55.
29. Latonkic BV, Zeremski M, Lau LF. Elk-1 can recruit SRF to form a ternary complex upon the serum response element. Nucleic Acids Res 1996, 24:1345-51. 10.1093/nar/24.7.1345, 145793, 8614640.
30. Townsend KJ, Zhou P, Qian L, Bieszczad CK, Lowrey CH, Yen A, Craig RW. Regulation of MCL1 through a serum response factor/Elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation. J Biol Chem 1999, 274:1801-13. 10.1074/jbc.274.3.1801, 9880563.
31. Kasza A, Wyrzykowska P, Horwacik I, Tymoszuk P, Mizgalska D, Palmer K, Rokita H, Sharrocks AD, Jura J. Transcription factors Elk-1 and SRF are engaged in IL1-dependent regulation of ZC3H12 expression. BMC Mol Biol 2010, 11:14. 10.1186/1471-2199-11-14, 2829564, 20137095.
32. Wyrzykowska P, Stalińska K, Wawro M, Kochan J, Kasza A. Epidermal growth factor regulates PAI-1 expression via activation of the transcription factor Elk-1. Biochim Biophys Acta - Gene Regul Mech 2010, 1799:616-21.
33. Baillat D, Begue A, Stehelin D, Aumercier M. ETS-1 transcription factor binds cooperatively to the palindromic head to head ETS-binding sites of the stromelysin-1 promoter by counteracting autoinhibition. J Biol Chem 2002, 277:29386-29398. 10.1074/jbc.M200088200, 12034715.
34. Baillat D, Laitem C, Leprivier G, Margerin C, Aumercier M. Ets-1 binds cooperatively to the palindromic Ets-binding sites in the p53 promoter. Biochem Biophys Res Commun 2009, 378:213-217. 10.1016/j.bbrc.2008.11.035, 19022222.
35. Gille H, Kortenjann M, Strahl T, Shaw PE. Phosphorylation-Dependent Formation of a Quaternary Complex at the c-fos SRE. Mol and Cel Biol 1996, 16:1094-1102.
36. Drewett V, Muller S, Goodall J, Shaw PE. Dimer formation by ternary complex factor ELK-1. J Biol Chem 2000, 275:1757-62. 10.1074/jbc.275.3.1757, 10636872.
37. Shukla AA, Jain M, Chauhan SS. Ets-1/ELK-1 is a critical mediator of dipeptidyl-peptidase III transcription in human glioblastoma cells. FEBS J 2010, 277:1861-1875. 10.1111/j.1742-4658.2010.07603.x, 20236318.
38. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM. Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J 2007, 21:3763-70. 10.1096/fj.07-8832com, 17586727.
39. Xue C, Wyckoff J, Liang F, Sidani M, Violini S, Tsai KL, Zhang ZY, Sahai E, Condeelis J, Segall JE. Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 2006, 66:192-7. 10.1158/0008-5472.CAN-05-1242, 16397232.
40. Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci USA 2009, 106:3372-7. 10.1073/pnas.0813306106, 2642666, 19218449.
41. Menard S, Fortis M, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. Oncology 2001, 61:67-72. 10.1159/000055404, 11694790.
42. Stoecklin G, Gross B, Ming XF, Moroni C. A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA. Oncogene 2003, 22:3554-61. 10.1038/sj.onc.1206418, 12789264.
43. Essafi-Benkhadir K, Onesto C, Stebe E, Moroni C, Pagès G. Tristetraprolin inhibits Ras-dependent tumor vascularization by inducing vascular endothelial growth factor mRNA degradation. Mol Biol Cell 2007, 18:4648-58. 10.1091/mbc.E07-06-0570, 2043565, 17855506.
44. Brennan SE, Kuwano Y, Alkharouf N, Blackshear PJ, Gorospe M, Wilson GM. The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res 2009, 69:5168-76. 10.1158/0008-5472.CAN-08-4238, 2724875, 19491267.